Summary of Study ST002865
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001786. The data can be accessed directly via it's Project DOI: 10.21228/M8VB1G This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002865 |
| Study Title | Metabolic profiling, glucose tracing and glutamine tracing in 16D prostate cancer cells treated with vehicle, AR inhibitor Enzalutamide, AR inhibitor Apalutamide, or AR degrader/PROTAC ARCC-4 |
| Study Summary | Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploit therapy-induced phenotypes prior to the outgrowth of treatment-resistant disease. Here, we comprehensively characterize the effect of AR blockade on prostate cancer metabolism using transcriptomics, metabolomics and bioenergetics approaches. The metabolic response to AR inhibition is defined by reduced glycolysis, robust elongation of mitochondria, and increased reliance on mitochondrial oxidative metabolism. We establish DRP1 activity and MYC signaling as mediators of AR blockade-induced metabolic phenotypes. Rescuing DRP1 phosphorylation after AR inhibition restores mitochondrial fission, while rescuing MYC restores glycolytic activity and prevents sensitivity to complex I inhibition. Our study provides new insight into the regulation of treatment-induced metabolic phenotypes and vulnerabilities in prostate cancer. In the MS data, M0, M1, M2, M3,... represent isotopologues of each metabolite. |
| Institute | University of California, Los Angeles |
| Department | Molecular, Cell and Developmental Biology |
| Laboratory | Andrew Goldstein |
| Last Name | Goldstein |
| First Name | Andrew |
| Address | 610 Charles E Young Dr East, Goldstein Lab 3141 Terasaki Life Sci Bld, Los Angeles, CA, 90095, USA |
| AGoldstein@mednet.ucla.edu | |
| Phone | 3102061402 |
| Submit Date | 2023-09-12 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-09-19 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment |
|---|---|---|
| SA309483 | NN.009 | Apalutamide_C13Glc |
| SA309484 | NN.008 | Apalutamide_C13Glc |
| SA309485 | NN.007 | Apalutamide_C13Glc |
| SA309486 | NN.019 | Apalutamide_C13Gln |
| SA309487 | NN.021 | Apalutamide_C13Gln |
| SA309488 | NN.020 | Apalutamide_C13Gln |
| SA309477 | NN.012 | ARCC4_C13Glc |
| SA309478 | NN.010 | ARCC4_C13Glc |
| SA309479 | NN.011 | ARCC4_C13Glc |
| SA309480 | NN.022 | ARCC4_C13Gln |
| SA309481 | NN.024 | ARCC4_C13Gln |
| SA309482 | NN.023 | ARCC4_C13Gln |
| SA309489 | NN.005 | Enzalutamide_C13Glc |
| SA309490 | NN.004 | Enzalutamide_C13Glc |
| SA309491 | NN.006 | Enzalutamide_C13Glc |
| SA309492 | NN.018 | Enzalutamide_C13Gln |
| SA309493 | NN.017 | Enzalutamide_C13Gln |
| SA309494 | NN.016 | Enzalutamide_C13Gln |
| SA309495 | QC.blank1 | NA |
| SA309496 | QC.blank2 | NA |
| SA309497 | QC.blank3 | NA |
| SA309498 | NN.003 | Vehicle_C13Glc |
| SA309499 | NN.001 | Vehicle_C13Glc |
| SA309500 | NN.002 | Vehicle_C13Glc |
| SA309501 | NN.014 | Vehicle_C13Gln |
| SA309502 | NN.013 | Vehicle_C13Gln |
| SA309503 | NN.015 | Vehicle_C13Gln |
| Showing results 1 to 27 of 27 |
